title: Acceptability of home use of mifepristone for medical abortion.
abstract: BACKGROUND
  Most medical abortion protocols require women to take mifepristone in the doctor's office. We assessed the acceptability of home use of mifepristone among women and their providers.
  
  
  METHODS
  In this multicenter trial, eligible women requesting termination of early pregnancy (n=301) chose whether to take mifepristone in the office or at home. Data on safety, efficacy, acceptability and disability were collected.
  
  
  RESULTS
  One hundred thirty-nine women (46%) chose to take mifepristone at home, and 162 (54%) chose office administration. Ninety-five percent of home users said that they would take the mifepristone in the same place in the future. Home users were not more likely to call the doctor's office or make an unplanned visit, and providers would recommend home use again for 95% of patients who chose home use.
  
  
  CONCLUSIONS
  Home administration of mifepristone was safe and acceptable to women and providers in our study. Women should be offered this choice to allow more flexibility, comfort and privacy in their abortion experiences.
authors.affiliation: Center for Family and Community Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
authors.forename: Yael
authors.initials: Y
authors.lastname: Swica
authors.forename: Erica
authors.initials: E
authors.lastname: Chong
authors.forename: Tamer
authors.initials: T
authors.lastname: Middleton
authors.forename: Linda
authors.initials: L
authors.lastname: Prine
authors.forename: Marji
authors.initials: M
authors.lastname: Gold
authors.forename: Courtney A
authors.initials: CA
authors.lastname: Schreiber
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D001291:Attitude of Health Personnel; D020070:Cervical Ripening / Q000187:drug effects; D002755:Choice Behavior; D005260:Female; D005500:Follow-Up Studies; D005845:Georgia; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D009519:New York City; D057240:Patient Preference; D015143:Philadelphia; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011300:Preoperative Care / Q000009:adverse effects; D012646:Self Administration; D055815:Young Adult
chemical_list: D000021:Abortifacient Agents, Steroidal; D015735:Mifepristone